Their potential is huge—in 2023 alone, generic and biosimilar medications created $445 billion in savings across the health-care system, benefiting patients, employers, and taxpayers alike.

The FDA approved omalizumab-igec (Omlyclo) as the first biosimilar for omalizumab (Xolair) and the first for any respiratory ...

Dr. Reddy’s Laboratories RDY and partner, Alvotech ALVO, announced the FDA’s acceptance of a regulatory filing, seeking the ...

Biosimilars, copies of off-patent biopharmaceuticals, offer healthcare systems a way to broaden patient access to medicines without compromising on quality, safety, or efficacy. However ...

Alvotech’s CEO highlighted the move as a significant step towards strengthening the company’s position in the biosimilars market and enhancing patient access to biologics globally. Acquisition ...

Patients who received the biosimilar in the first period continued to do so at week 52; those who received Prolia were randomly assigned to continue the treatment or switch to the biosimilar during ...

Celltrion, Inc., a leading global biopharmaceutical company, announced today that its infliximab biosimilar will be marketed in Canada under the new b ...

Given the high cost of branded drugs, a biosimilar alternative could provide substantial financial relief to patients and healthcare systems. Additionally, with osteoporosis affecting millions ...